Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) rose 5% Tuesday morning on news the FDA has approved its wearable treatment device Onapgo, formerly known as SPN-830, for the treatment of patients ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...

The adjustment came following the FDA's approval of Onapgo, a new treatment for OFF episodes in Parkinson's disease patients. According to InvestingPro data, Supernus demonstrates strong financial ...

Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...

President and CEO of Supernus. “In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025 ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...

About Supernus Pharmaceuticals ... to commercialize its products and the products of its subsidiaries including ONAPGO; the Company’s ability to enter into future collaborations with ...

Ritz-Carlton South Beach, Miami, Fla. Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.

President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025; and further ...

President and CEO of Supernus. "In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson's disease, planned for the second quarter of 2025 ...